Research Topics
| E HawkSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Can animal models help us select specific compounds for cancer prevention trials?Ernest T Hawk
GI and Other Cancers Research Group, National Cancer Institute, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
Recent Results Cancer Res 166:71-87. 2005....- Biomarkers as surrogates for cancer developmentE Hawk
DCP GI and Other Cancer Research Group, National Cancer Institute, EPN, Suite 201, 6130 Executive Boulevard, Bethesda, MD 20892 7322, USA
Curr Oncol Rep 2:242-50. 2000..A step-wise approach to the development of tissue-based biomarkers is presented. These biomarkers may serve as molecular targets for scientific inquiry and intervention, as well as approvable endpoints for clinical trials... - Do statins prevent cancer?Ernest T Hawk
Office of Centers, Training and Resources at the National Cancer Institute, Bethesda, MD 20892, USA
Nat Clin Pract Oncol 3:478-9. 2006 - Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination SurveyE Hawk
Gastrointestinal and Other Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892 7322, USA
Cancer Epidemiol Biomarkers Prev 9:523-7. 2000..50 (95% confidence interval, 1.12-2.00) and was similar regardless of the severity of baldness at baseline and was independent of other risk factors, including race and age. MPB seems to be a risk factor for clinical prostate cancer... - Celecoxib for the prevention of sporadic colorectal adenomasMonica M Bertagnolli
Brigham and Women s Hospital, Boston, USA
N Engl J Med 355:873-84. 2006.... - Colorectal cancer chemoprevention--an overview of the scienceErnest T Hawk
Gastrointentinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute NIH, EPN Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
Gastroenterology 126:1423-47. 2004..Innovative research models include the nesting of prevention end points within cancer treatment trials and within trials testing promising preventive compounds intended for nononcologic indications... - Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patientsFrank A Sinicrope
Department of Gastrointestinal Medicine and Nutrition, University of Texas M D Anderson Cancer Center, Houston, USA
Cancer Epidemiol Biomarkers Prev 13:920-7. 2004.... - Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer preventionErnest T Hawk
National Cancer Institute, Division of Cancer Prevention, Bethesda, MD 20892-7317, USA
Cancer Chemother Biol Response Modif 21:759-89. 2003 - Prevention and therapy of colorectal cancerErnest T Hawk
Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
Med Clin North Am 89:85-110, viii. 2005..These advances substantiate target-driven approaches to cancer prevention and treatment, and provide fruitful opportunities for future investigations... - Colorectal cancer preventionErnest T Hawk
GI and Other Cancers Research Group, National Cancer Institute, 6130 Executive Boulevard, Suite 2141, Bethesda, MD 20892 7322, USA
J Clin Oncol 23:378-91. 2005..The threshold for tolerating toxicities is very low in asymptomatic individuals at minimally increased risk for colorectal neoplasia... - Workshop on imaging science development for cancer prevention and preemptionGary J Kelloff
NIH NCI DCTD, Cancer Imaging Program, Bethesda, MD, USA
Cancer Biomark 3:1-33. 2007..Imaging devices, alone or in combination with anticancer drugs, may also provide novel interventions to treat or prevent precancer... - A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancerJanusz A Jankowski
Department of Clinical Pharmacology, Radcliffe Infirmary, Oxford University, UK
Nat Clin Pract Gastroenterol Hepatol 3:101-11. 2006..In this review we systematically assess the evidence for various cancer prevention strategies, especially chemoprevention, and highlight the obstacles to further exploitation of this knowledge base... - Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forwardGary J Kelloff
National Cancer Institute, Bethesda, Maryland 20852, USA
Clin Cancer Res 12:3661-97. 2006.... - Serum proteomic profiles suggest celecoxib-modulated targets and response predictorsZhen Xiao
Laboratory of Proteomics and Analytical Technologies and Advanced Biomedical Computing Center, SAIC-Frederick Inc, National Cancer Institute at Frederick, Frederick, Maryland, USA
Cancer Res 64:2904-9. 2004..In particular, a spectral feature at m/z 16,961.4 was identified as a strong discriminator between response and nonresponse to celecoxib at the highest dose... 
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instabilityAsad Umar
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
J Natl Cancer Inst 96:261-8. 2004....- Testing guidelines for hereditary non-polyposis colorectal cancerAsad Umar
Division of Cancer Prevention and Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Nat Rev Cancer 4:153-8. 2004 - The role of cyclooxygenase inhibitors in cancer preventionWilliam F Anderson
Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Room 2141, 6130 Executive Boulevard, Bethesda, MD 20892-7317, USA
Curr Pharm Des 8:1035-62. 2002..Nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) -1 and -2 are among the most promising classes of agents for targeted molecular prevention... - Chemoprevention of colorectal cancer: problems, progress, and prospectsJaye L Viner
Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892-7317, USA
Gastroenterol Clin North Am 31:971-99. 2002..The number of trials that are investigating chemopreventives against CR neoplasia is relatively small; if these agents live up to a fraction of their promise, the public health impact may be great (see Table 6)... - Chemoprevention of colorectal carcinogenesisAsad Umar
Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
Int J Clin Oncol 7:2-26. 2002..These targets will help identify more effective and better tolerated preventive agents. Carcinogenesis is now recognized as a disease in itself and has become the target of an ever-expanding array of preventive interventions... - Epidemiology and prevention of colorectal cancerErnest T Hawk
Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
Surg Clin North Am 82:905-41. 2002..The challenges and rewards of participation in chemoprevention research--both as patients and health care providers-have never been greater... - Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancerVernon E Steele
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892 7322, USA
Mutat Res 523:137-44. 2003..As newer more specific drugs are developed with few adverse effects this important prevention strategy may become a reality... - Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trialsErnest T Hawk
Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, MD, USA
Prog Exp Tumor Res 37:210-42. 2003 - Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancersGary J Kelloff
National Cancer Institute, Division of Cancer Treatment and Diagnosis, Biomedical Imaging Program, Bethesda, Maryland 20892, USA
Cancer Epidemiol Biomarkers Prev 12:593-6. 2003 - Development of COX inhibitors in cancer prevention and therapyAsad Umar
Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland 20892-7317, USA
Am J Clin Oncol 26:S48-57. 2003..Discovering how to apply NSAIDs in persons with-or at risk for-cancer, although challenging, has the potential for considerable clinical and public health benefits... - Cyclooxygenase inhibition in cancer prevention and treatmentWilliam F Anderson
Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, EPN, Room 2141, 6130 Executive Boulevard, Bethesda, MD 20892-7317, USA
Expert Opin Pharmacother 4:2193-204. 2003..A brief discussion on the pharmacoeconomic considerations of NSAID and COXIB use and safety issues that have recently been the focus of debate, will be presented... - COX-2 in cancer--a player that's defining the rulesErnest T Hawk
J Natl Cancer Inst 94:545-6. 2002 - Statins in esophageal cancer cell lines: promising lead?Ernest T Hawk
Am J Gastroenterol 103:838-41. 2008.... 
The Translational Research Working Group developmental pathways: introduction and overviewErnest T Hawk
Office of Centers, Training, and Resources, National Cancer Institute, Rockville, Maryland, USA
Clin Cancer Res 14:5664-71. 2008..Further development of the pathways is encouraged, as is application of the pathway concept to translational research on other diseases...- Translational Research Working Group developmental pathway for biospecimen-based assessment modalitiesSudhir Srivastava
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
Clin Cancer Res 14:5672-7. 2008..This paper introduces the pathway in the context of prior work and discusses key challenges associated with the biomarker development process in light of the pathway... - Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese populationNina Joshi
Genetics Branch, Center for Cancer Research, National Cancer Institute/NIH, EPS, 6120 Executive Boulevard, Bethesda, MD 20892, USA
Cancer Res 66:6851-60. 2006..These data suggest that local and systemic immune responses may influence the natural history of esophageal squamous dysplasia... - Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk Chinese populationNina Joshi
Amgen, 1201 Amgen Court West, AW1-J 4144, Seattle, WA 98119-3105, USA
Cancer Epidemiol Biomarkers Prev 15:1046-7. 2006.... - Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxibPaul J Limburg
Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Gastroenterology 129:863-73. 2005..Squamous dysplasia, the accepted histological precursor for esophageal squamous cell carcinoma, represents a potentially modifiable intermediate end point for chemoprevention trials in high-risk populations... - Irreversible ototoxicity associated with difluoromethylornithineChristopher D Lao
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, 48109, USA
Cancer Epidemiol Biomarkers Prev 13:1250-2. 2004..This is the first case reported of irreversible ototoxicity in a clinical trial participant receiving DFMO and, thus, trial participants should be made aware of this small but important risk... - Frontiers in cancer prevention researchAnita L Sabichi
Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
Cancer Res 63:5649-55. 2003 - The Translational Research Working Group developmental pathway for lifestyle alterationsErnest T Hawk
National Cancer Institute, Bethesda, Maryland, USA
Clin Cancer Res 14:5707-13. 2008..This article discusses key issues associated with the development of lifestyle alterations in light of the pathway...